• KalVista Pharmaceuticals released new analyses on pediatric hereditary angioedema, with findings presented at ISPOR 2026 and scheduled for the Eastern Allergy Conference.
• Claims data suggested many families rely on off-label, less invasive on-demand options, despite IV therapy being the only FDA-cleared choice for ages 2-11.
• Survey results indicated injectable treatment burden drives anxiety, delayed dosing, missed treatment, caregiver difficulty, and frequent emergency-care use.
• The company plans a pediatric NDA for sebetralstat in Q3 2026, positioning its oral on-demand approach as a potential alternative.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260528516882) on May 28, 2026, and is solely responsible for the information contained therein.